Compare · BNTX vs RVMD
BNTX vs RVMD
Side-by-side comparison of BioNTech SE (BNTX) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $42.84B, about 1.8x BNTX ($24.05B).
- Over the past year, BNTX is down 10.2% and RVMD is up 331.4% - RVMD leads by 341.5 points.
- RVMD has been more active in the news (21 items in the past 4 weeks vs 14 for BNTX).
- Both have 25 recent analyst ratings on file.
- Company
- BioNTech SE
- Revolution Medicines Inc.
- Price
- $95.23-0.54%
- $200.89+0.49%
- Market cap
- $24.05B
- $42.84B
- 1M return
- -3.56%
- -3.08%
- 1Y return
- -10.18%
- +331.37%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 14
- 21
- Recent ratings
- 25
- 25
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest BNTX
- SEC Form 4 filed by BioNTech SE
- SEC Form 4 filed by BioNTech SE
- Chief Executive Officer Sahin Ugur sold $3,301,068 worth of Ordinary Shares (34,000 units at $97.09) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 180,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,480,659 worth of Ordinary Shares (66,000 units at $98.19) as part of a pre-agreed trading plan, decreasing direct ownership by 24% to 214,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,012,500 worth of Ordinary Shares (61,000 units at $98.57) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 280,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,842,742 worth of Ordinary Shares (69,000 units at $99.17) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 341,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $7,860,757 worth of Ordinary Shares (79,000 units at $99.50) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 410,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,239,071 worth of Ordinary Shares (64,000 units at $97.49) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 489,209 units (SEC Form 4)
- SEC Form 6-K filed by BioNTech SE
- Chief Executive Officer Sahin Ugur sold $4,721,976 worth of Ordinary Shares (49,000 units at $96.37) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 553,209 units (SEC Form 4)
Latest RVMD
- Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
- Chief Development Officer Sandler Alan B. exercised 6,000 shares at a strike of $58.84 and sold $1,275,294 worth of shares (6,309 units at $202.14) as part of a pre-agreed trading plan, decreasing direct ownership by 0.58% to 52,559 units (SEC Form 4)
- SVP & General Counsel Cislini Jeff sold $158,600 worth of shares (765 units at $207.32) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 51,776 units (SEC Form 4)
- Officer Mancini Anthony sold $743,285 worth of shares (3,708 units at $200.45) as part of a pre-agreed trading plan and exercised 3,121 shares at a strike of $33.62, decreasing direct ownership by 1% to 39,765 units (SEC Form 4)
- KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
- Director Anderson Elizabeth M exercised 5,070 shares at a strike of $1.12 and sold $1,958,016 worth of shares (10,143 units at $193.04) as part of a pre-agreed trading plan, decreasing direct ownership by 54% to 4,333 units (SEC Form 4)
- Goldman resumed coverage on Revolution Medicines with a new price target
- Officer Mancini Anthony sold $347,402 worth of shares (1,764 units at $196.94) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 40,352 units (SEC Form 4)
- Chief Development Officer Sandler Alan B. sold $67,941 worth of shares (341 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 52,868 units (SEC Form 4) to satisfy withholding tax
- Officer Mancini Anthony sold $353,449 worth of shares (1,774 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 42,116 units (SEC Form 4) (for tax liability)